215 related articles for article (PubMed ID: 8993250)
1. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass.
Moen O; Høgåsen K; Fosse E; Dregelid E; Brockmeier V; Venge P; Harboe M; Mollnes TE
Ann Thorac Surg; 1997 Jan; 63(1):105-11. PubMed ID: 8993250
[TBL] [Abstract][Full Text] [Related]
2. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems.
Moen O; Fosse E; Brockmeier V; Andersson C; Mollnes TE; Høgåsen K; Venge P
Ann Thorac Surg; 1995 Nov; 60(5):1317-23. PubMed ID: 8526620
[TBL] [Abstract][Full Text] [Related]
3. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
Fosse E; Thelin S; Svennevig JL; Jansen P; Mollnes TE; Hack E; Venge P; Moen O; Brockmeier V; Dregelid E; Haldén E; Hagman L; Videm V; Pedersen T; Mohr B
Eur J Cardiothorac Surg; 1997 Feb; 11(2):320-7. PubMed ID: 9080162
[TBL] [Abstract][Full Text] [Related]
4. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits.
Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Abdelnoor M; Ringdal MA; Oystese R; Venge P
J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1623-32. PubMed ID: 8523872
[TBL] [Abstract][Full Text] [Related]
5. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
[TBL] [Abstract][Full Text] [Related]
6. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo.
Videm V; Mollnes TE; Bergh K; Fosse E; Mohr B; Hagve TA; Aasen AO; Svennevig JL
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):803-9. PubMed ID: 10096977
[TBL] [Abstract][Full Text] [Related]
7. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes.
Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Ringdal MA; Videm V
Ann Thorac Surg; 1995 Dec; 60(6):1755-61. PubMed ID: 8787476
[TBL] [Abstract][Full Text] [Related]
8. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility.
Moen O; Fosse E; Dregelid E; Brockmeier V; Andersson C; Høgåsen K; Venge P; Mollnes TE; Kierulf P
Ann Thorac Surg; 1996 Oct; 62(4):1134-40. PubMed ID: 8823102
[TBL] [Abstract][Full Text] [Related]
9. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population.
Videm V; Mollnes TE; Fosse E; Mohr B; Bergh K; Hagve TA; Aasen AO; Svennevig JL
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):794-802. PubMed ID: 10096976
[TBL] [Abstract][Full Text] [Related]
10. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
[TBL] [Abstract][Full Text] [Related]
11. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
[TBL] [Abstract][Full Text] [Related]
12. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
Fukutomi M; Kobayashi S; Niwaya K; Hamada Y; Kitamura S
Artif Organs; 1996 Jul; 20(7):767-76. PubMed ID: 8828766
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery.
Hoel TN; Videm V; Baksaas ST; Mollnes TE; Brosstad F; Svennevig JL
Perfusion; 2004 May; 19(3):177-84. PubMed ID: 15298426
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass.
Lundblad R; Moen O; Fosse E
Ann Thorac Surg; 1997 May; 63(5):1361-7. PubMed ID: 9146328
[TBL] [Abstract][Full Text] [Related]
15. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass.
Gu YJ; van Oeveren W; Akkerman C; Boonstra PW; Huyzen RJ; Wildevuur CR
Ann Thorac Surg; 1993 Apr; 55(4):917-22. PubMed ID: 8466349
[TBL] [Abstract][Full Text] [Related]
16. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass.
Fosse E; Moen O; Johnson E; Semb G; Brockmeier V; Mollnes TE; Fagerhol MK; Venge P
Ann Thorac Surg; 1994 Aug; 58(2):472-7. PubMed ID: 8067851
[TBL] [Abstract][Full Text] [Related]
17. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation.
Ovrum E; Fosse E; Mollnes TE; Am Holen E; Tangen G; Abdelnoor M; Ringdal MA; Oystese R; Venge P
Eur J Cardiothorac Surg; 1996; 10(1):54-60. PubMed ID: 8776186
[TBL] [Abstract][Full Text] [Related]
18. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences.
Wimmer-Greinecker G; Matheis G; Martens S; Oremek G; Abdel-Rahman U; Moritz A
Eur J Cardiothorac Surg; 1999 Aug; 16(2):211-7. PubMed ID: 10485423
[TBL] [Abstract][Full Text] [Related]
19. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations.
Videm V; Svennevig JL; Fosse E; Semb G; Osterud A; Mollnes TE
J Thorac Cardiovasc Surg; 1992 Apr; 103(4):806-13. PubMed ID: 1548925
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
